Passa al contenuto
Merck
  • Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models.

Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models.

Bioorganic & medicinal chemistry letters (2010-11-16)
Eugen F Mesaros, Jason P Burke, Jonathan D Parrish, Benjamin J Dugan, Andrew V Anzalone, Thelma S Angeles, Mark S Albom, Lisa D Aimone, Matthew R Quail, Weihua Wan, Lihui Lu, Zeqi Huang, Mark A Ator, Bruce A Ruggeri, Mangeng Cheng, Gregory R Ott, Bruce D Dorsey
ABSTRACT

The synthesis and biological evaluation of potent and selective anaplastic lymphoma kinase (ALK) inhibitors from a novel class of 2,4-diaminopyrimidines, incorporating 2,3,4,5-tetrahydro-benzo[d]azepine fragments, is described. An orally bioavailable analogue (18) that displayed antitumor efficacy in ALCL xenograft models in mice was identified and extensively profiled.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
2,4-Diaminopyrimidine, 98%